An observational study in Myocarditis, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Myocarditis with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Myocarditis · China.
Among the 14 studies in Myocarditis with a site in China, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2023, is one of 10 observational ones, and was the 5th registered.
175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.
Browse Myocarditis studies →10 of the 14 studies in Myocarditis with a site in China are open now. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18–80
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Shanghai Chest Hospital · Sites in China
Ages 18+
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 3–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 53 Myocarditis studies recruiting now, 32 (60%) set no upper age limit and 6 (11%) stop at 75 or younger; 15 take children under 18; 14 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 200 across 121 observational studies indexed under Myocarditis.
Median enrollment 80 across the 4 interventional studies, 287 across the 10 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.
First Affiliated Hospital Xi'an Jiaotong University has 2 studies filed under Myocarditis — fewer than ten, so there is no comparison to draw.
1 of the studies in Myocarditis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354646Chinese Academy of Medical Sciences, Fuwai HospitalThe Application of T1 Mapping in Real-World | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Myocarditis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to understand how myocarditis, an inflammation of the heart muscle, presents, changes over time, and affects long-term health in patients of all ages in China. The study also aims to build a collection of blood, other body fluids, and tissue samples linked to patients' medical information to support future research.
The main questions it aims to answer are:
This is an amendment to the ongoing FORWARD study, not a new study. The registry aims to include approximately 5,000 patients using both existing medical records and ongoing enrollment.
For patients taking part in prospective follow-up, participation will involve:
No extra clinic visits, tests, or needle insertions are required solely for this study. Sample collection depends on clinical opportunities, patient safety, and consent. Patients may participate in the clinical registry and follow-up without providing samples.
FORWARD is an ongoing, investigator-initiated, nationwide multicenter observational registry cohort study of patients with myocarditis in China. This registration update reflects an amendment to the existing study registered as NCT06010199. The amendment refines the study's scope, eligibility, retrospective coverage, prospective recruitment, follow-up, and biospecimen resource development. Previously enrolled participants retain their original study identifiers and observation timelines. New or modified research activities will be implemented following applicable ethics approval.
The objectives are to characterize clinical phenotypes, diagnostic findings, treatment patterns, disease course, and long-term outcomes, and to develop a traceable biospecimen resource linked to longitudinal clinical information. The platform will support future clinical and translational research. Specific subsequent projects will require separate protocols and applicable approvals, identify FORWARD as the source of their data and samples, and remain within the relevant consent and authorization scope.
Study population and design
Patients of all ages and sexes with myocarditis diagnosed by qualified treating physicians at participating centers are eligible, subject to the protocol criteria. Recruitment includes outpatient, inpatient, and intensive care settings, including patients receiving mechanical circulatory support or heart transplantation. First episodes, recurrent disease, persistent disease, and recovery phases may be included.
Diagnosis is based on clinical assessment and available laboratory, electrocardiographic, imaging, and, when clinically obtained, histopathological findings, with reference to guidelines and diagnostic standards applicable to the patient's age and period of care. Cardiac magnetic resonance imaging and endomyocardial biopsy are not mandatory for every participant, and no diagnostic procedure is performed solely to establish research eligibility. Updates to diagnostic standards will be documented, while original diagnoses and supporting records will be preserved.
The study combines retrospective and prospective components. Retrospective coverage extends from January 1, 2003, through the protocol amendment date. Prospective recruitment will continue through December 31, 2045. The target registry size is approximately 5,000 unique patients, including eligible previously enrolled, retrospectively identified, and newly recruited participants. This target is a resource-development goal rather than a fixed recruitment cap. Repeated encounters, recurrent episodes, and repeated samples are linked to the same participant identifier.
No treatment is assigned by the study. Medications, investigations, procedures, mechanical circulatory support, and transplantation are determined independently by treating clinicians.
Clinical data and observation periods
Clinical data include demographics, symptom onset, diagnosis and diagnostic evidence, clinical presentation, disease severity, comorbidities, laboratory results, electrocardiography, cardiac imaging, available pathology, treatments, and clinical events. Dates of symptom onset, diagnosis, registry entry, and sample collection are recorded separately.
The clinical baseline is generally the first qualifying encounter or hospitalization within the observation period. Core follow-up assessments are scheduled at 1, 3, 6, and 12 months and annually during years 2 through 5. Information is obtained through routine care visits, hospital records, existing medical records, and telephone contact. Hospitalized patients also have information recorded during admission and at discharge. Study-specific visits or additional clinical investigations are not required.
Historical outcomes are reconstructed from available records without creating retrospective visits. Participants whose original five-year observation period is incomplete may continue for the remaining period. For historical patients whose five-year observation period has already ended, a separate five-year prospective observation phase may begin at registry entry after the applicable consent process. Historical and newly initiated prospective observation periods are recorded and analyzed separately. Existing observation periods are not restarted by the amendment. New prospective observation phases will generally begin by December 31, 2045, with scheduled follow-up completed by December 31, 2050.
Outcomes and comparisons
The primary outcome is the first occurrence of a composite of all-cause death, heart transplantation, hospitalization for heart failure, or serious ventricular arrhythmia within one year after the clinical baseline. Serious ventricular arrhythmia includes sustained ventricular tachycardia, ventricular fibrillation, or resuscitated arrhythmic cardiac arrest. Sustained ventricular tachycardia is defined as lasting at least 30 seconds or requiring earlier termination because of hemodynamic instability. Individual components are also reported.
For participants with a hospitalization-based baseline, the index hospitalization does not count as a heart failure hospitalization outcome. Other qualifying events occurring after baseline during that admission remain eligible. Subsequent hospitalization for new or worsening heart failure is counted, and continuous transfers are treated as a single hospitalization. For an outpatient baseline, the first subsequent hospitalization for new or worsening heart failure is eligible.
Secondary outcomes include the specified clinical events at 30 days, 90 days, six months, and years 2 through 5; recurrent hospitalizations; use and duration of mechanical circulatory support; myocarditis recurrence; changes in cardiac function and structure; functional status; and other arrhythmias or conduction abnormalities. Registry performance measures include data completeness, follow-up completion, biospecimen availability, longitudinal sample coverage, and sample quality.
Comparisons are observational and based on clinical presentation, disease severity, episode status, disease phase, diagnostic evidence, age, sex, comorbidities, center, and period of care. Clinical presentations include chest pain, heart failure, arrhythmia, mixed presentations, and other or minimally symptomatic presentations. These strata do not determine treatment.
Optional biospecimen collection
Biospecimens may be obtained at baseline and any follow-up time point when a suitable clinical sampling opportunity exists and the applicable consent has been obtained. Blood and other body fluids are collected as additional research aliquots during the same sampling procedure already required for clinical care. Research blood is additional blood collected at that time, not leftover blood from clinical testing. No separate research-only puncture or additional sampling procedure is performed.
Patient safety, clinical needs, and participant preferences take priority. Treating clinicians determine whether collection is appropriate and the amount that can safely be obtained, considering age, body weight, clinical condition, recent cumulative sampling, and willingness to participate. There is no mandatory minimum sample volume. Tissue is limited to material remaining after clinical care and pathological diagnostic requirements have been met; no additional biopsy or extension of surgery is performed for research.
Previously stored samples may be used only after verification of their source, storage records, and applicable authorization or ethics approval. Lack of samples, insufficient sample volume, or refusal of sample collection does not prevent enrollment or continued clinical follow-up. Sample timing, type, quantity, disease status, treatment context, and processing information are linked to clinical records using coded identifiers.
Consent, data quality, and analysis
Retrospective data and previously stored samples are used within applicable consent or ethics-approved waiver arrangements. Prospective participants complete the applicable consent process. For eligible adults participating only in clinical registration and noninvasive follow-up without any research biospecimen use, a waiver of consent signature may be used only where specifically approved; explicit oral consent and approved process documentation remain required. Other participants follow the applicable written consent procedures. Minors require guardian consent and age-appropriate involvement in the decision, with confirmation by the participant upon reaching adulthood.
Data and samples are managed using unique identifiers, restricted access, standardized definitions, and quality checks. Analyses will describe clinical characteristics and outcomes and evaluate associations while considering confounding, center effects, and changes in diagnostic practice over time. Time-to-event, competing-risk, recurrent-event, and longitudinal methods will be used as appropriate. Historical observation and separately initiated prospective observation will be analyzed separately. The platform protocol does not include development of prediction models.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Patients of all ages and sexes with physician-diagnosed myocarditis receiving routine care at the First Affiliated Hospital of Xi'an Jiaotong University and other FORWARD centers in China. Sources include outpatient clinics, inpatient wards, intensive care units, and services providing mechanical circulatory support or heart transplantation. The population includes retrospectively identified patients with qualifying encounters from January 1, 2003, through the protocol amendment date, eligible previously enrolled participants, and patients recruited prospectively through December 31, 2045. First episodes, recurrent disease, persistent disease, and recovery phases are eligible. Patients may participate without providing biospecimens or attending additional in-person visits. Retrospectively identified patients who subsequently undergo prospective follow-up retain their original cohort assignment and unique identifier.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional Eligibility Clarifications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients of all ages with physician-diagnosed myocarditis identified retrospectively from clinical records covering January 1, 2003, through the protocol amendment date. Available diagnostic, treatment, and outcome data will be collected from existing records. Historical outcomes will be reconstructed for up to five years after the qualifying clinical baseline. Patients may continue the remaining observation period or, after completing the historical period and the applicable consent process, begin a separate five-year prospective observation phase. They retain their original cohort assignment and unique identifier. Historical and newly initiated observation periods are recorded and analyzed separately. Previously stored samples may be used within applicable authorization and ethics approval. Sample availability is not required for inclusion. No treatment is assigned by the study.
Patients of all ages with physician-diagnosed myocarditis enrolled prospectively in the existing FORWARD study or newly recruited through December 31, 2045, excluding those assigned to the retrospective cohort. Previously enrolled patients retain their original identifiers and observation timelines. Clinical data and outcomes are collected at baseline, during hospitalization when applicable, at 1, 3, 6, and 12 months, and annually during years 2 through 5, using routine visits, medical records, or telephone contact. Treatment remains determined by treating clinicians. Optional additional blood or other body fluids may be collected during clinically required sampling, with applicable consent and safety assessment; tissue is limited to material remaining after clinical and pathological needs are met. No research-only puncture is performed. Lack of samples does not affect enrollment or follow-up.
One-Year Cumulative Probability of All-Cause Death, Heart Transplantation, Heart Failure Hospitalization, or Serious Ventricular Arrhythmia
Cumulative probability of the first occurrence of all-cause death, heart transplantation, hospitalization for new or worsening heart failure, or serious ventricular arrhythmia within one year after the qualifying clinical baseline. Serious ventricular arrhythmia includes sustained ventricular tachycardia, ventricular fibrillation, or resuscitated arrhythmic cardiac arrest. Sustained ventricular tachycardia lasts at least 30 seconds or requires earlier termination because of hemodynamic instability. The index hospitalization is excluded only from the heart failure hospitalization component; other qualifying events after baseline during that admission are included. Continuous hospital transfers count as one admission. Each component is also reported separately. Outcomes from a separately initiated prospective observation phase are not pooled with historical baseline outcomes.
Time frame: From the qualifying clinical baseline through 1 year
Cumulative Probability of the Composite Clinical Outcome at Short- and Long-Term Follow-Up
Cumulative probability of the first occurrence of all-cause death, heart transplantation, hospitalization for new or worsening heart failure, or serious ventricular arrhythmia, using the same definitions as the primary outcome. Each component is reported separately. The timing and total number of recurrent heart failure hospitalizations are also recorded. The index hospitalization is excluded only from the heart failure hospitalization component, and continuous hospital transfers count as one admission. Events before the applicable observation start are recorded as history rather than new outcomes. Historical observation and any separately initiated prospective observation phase are analyzed separately.
Time frame: At 30 days, 90 days, 6 months, and 2, 3, 4, and 5 years after the applicable observation start
Cumulative Probability of All-Cause Death
Cumulative probability, expressed as a percentage, of death from any cause. Death dates are ascertained from available medical records and follow-up information.
Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
Cumulative Incidence of Heart Transplantation
Cumulative incidence, expressed as a percentage, of the first heart transplantation after the applicable observation start, verified from clinical records. Death before transplantation is treated as a competing event.
Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
Cumulative Incidence of First Heart Failure Hospitalization
Cumulative incidence, expressed as a percentage, of the first hospitalization for new or worsening heart failure. For an inpatient baseline, the index admission is excluded. For an outpatient baseline, the first subsequent qualifying admission is included. Continuous hospital transfers count as one admission. Death before a qualifying hospitalization is treated as a competing event.
Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
Cumulative incidence, expressed as a percentage, of the first documented episode of sustained ventricular tachycardia, ventricular fibrillation, or resuscitated arrhythmic cardiac arrest after the applicable observation start. Event definitions are the same as for the primary outcome. Death before a qualifying arrhythmia is treated as a competing event.
Time frame: At 30 days, 90 days, 6 months, and 1, 2, 3, 4, and 5 years after the applicable observation start
Number of Heart Failure Hospitalizations per Participant
Number of qualifying hospitalizations for new or worsening heart failure per participant during the observed period, including the first qualifying admission and subsequent admissions. For an inpatient baseline, the index admission is excluded. Continuous hospital transfers count as one admission.
Time frame: From the applicable observation start through 5 years
Cumulative Incidence of First Myocarditis Recurrence
Cumulative incidence, expressed as a percentage, of the first physician-confirmed recurrence of myocarditis after the applicable observation start. Recurrence requires new clinical manifestations with supporting objective evidence documented in routine care. Persistent symptoms or an isolated abnormal test result alone do not establish recurrence. Death before recurrence is treated as a competing event.
Time frame: From the applicable observation start through 5 years
Number of Myocarditis Recurrences per Participant
Number of distinct physician-confirmed recurrent myocarditis episodes per participant during the observed period. Each episode requires new clinical manifestations with supporting objective evidence. Repeated records referring to the same episode are counted once.
Time frame: From the applicable observation start through 5 years
Change From Baseline in Left Ventricular Ejection Fraction
Change in left ventricular ejection fraction, expressed in percentage points, calculated as the follow-up value minus the baseline value. Paired values are obtained from clinically indicated cardiac imaging using comparable measurement methods.
Time frame: Baseline and 1, 3, 6, and 12 months and years 2, 3, 4, and 5 after the applicable observation start, when clinically available
Percentage of Participants Receiving Mechanical Circulatory Support
Percentage of participants who receive mechanical circulatory support at least once during the applicable observation period, based on routine clinical records. Support already in use at the observation start is included if it continues into the observation period. Each participant is counted once regardless of the number of support episodes.
Time frame: From the applicable observation start through 5 years
Duration of Mechanical Circulatory Support per Episode
Duration of mechanical circulatory support, in days per episode, measured from documented initiation to discontinuation. Duration is summarized for episodes with verifiable start and end dates. Episodes still ongoing at the last observation are not treated as completed episodes.
Time frame: For support episodes observed from the applicable observation start through 5 years
Percentage of Participants With Other Arrhythmias
Percentage of participants with at least one documented new or recurrent arrhythmia other than the serious ventricular arrhythmias included in the primary outcome. Events are identified from clinically obtained electrocardiograms, rhythm monitoring, and medical records. A pre-existing arrhythmia without a documented new episode is not counted as an event.
Time frame: From the applicable observation start through 5 years
Percentage of Participants With Newly Documented Conduction Abnormalities
Percentage of participants with at least one conduction abnormality newly documented during the observation period, based on clinically obtained electrocardiograms or rhythm monitoring. An abnormality already documented at the applicable observation start is not counted as newly documented.
Time frame: From the applicable observation start through 5 years
Started Aug 2023 (actual). Primary completion is estimated for Dec 2046, 280 months after the start.
Of 70 non-industry observational studies under Myocarditis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 251. This study's planned 280 months is above that.
Counting every sponsor, half of 72 studies reached it within 69 months; a quarter within 22 and three quarters within 251.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2030 → Dec 2046 and completion Aug 2030 → Dec 2050.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →